2025年业绩合规性、流通业务增长及商誉连续减值遇问询 国发股份回复

Core Viewpoint - The company, Guofang Co., Ltd. (600538.SH), provided a response to the Shanghai Stock Exchange regarding its 2025 performance forecast, addressing concerns about revenue composition, growth in the pharmaceutical distribution business, and significant goodwill impairment [1] Group 1: Revenue and Performance - The company expects a revenue of approximately 330 million yuan for 2025, with a net revenue of 327.2 million yuan after deducting unrelated income of 2.4808 million yuan [1] - The pharmaceutical distribution business accounts for nearly 58% of total revenue, showing a year-on-year growth of 4.43%, while the judicial IVD and pharmaceutical manufacturing segments experienced declines of 10% and 23.44%, respectively [1] - The top five customers in the pharmaceutical distribution sector remain stable, while the judicial IVD sector has seen significant fluctuations due to intensified bidding competition [1] Group 2: Growth Justification - The company attributes the growth in the pharmaceutical distribution business primarily to increased sales to hospitals, particularly in collective procurement varieties and narcotic drugs [1] - The delivery method is mainly through home delivery or express services, with revenue recognized upon customer signature, aligning the 4.43% growth rate with the pharmaceutical market growth of approximately 4%-4.5% in the Beibu Gulf region [1] Group 3: Goodwill Impairment - The company disclosed that its subsidiary, Gaosheng Bio, has underperformed due to reduced budgets from public security clients and intense market competition, leading to significant goodwill impairment [1] - Following impairments of approximately 55 million yuan and 60 million yuan in 2023 and 2024, respectively, the company plans to recognize an additional impairment of about 62 million yuan in 2025 [1] - A sensitivity analysis indicates that further declines in revenue or gross margin for Gaosheng Bio may necessitate additional impairment, which could significantly impact the company's profits [1]